← Every company
Novo Nordisk A/S SEC Filings
What Novo Nordisk A/S has told the SEC happened, by the 8-K items and forms it filed under: when it reported results, who joined or left, what it bought or sold, and whether its auditor or its accounts ever changed.
NVO overview →Filings on file
12
since Feb 9, 2017
Warning signs
0
none filed
Last results
—
8-K item 2.02
Industry
Pharmaceutical Preparations
SIC 2834
Newest first
Each label is a form type or an 8-K item as filed; each row links to the filing.
| Filed | What it reports | Document |
|---|---|---|
| Feb 4, 2026 | Annual report 20-F | Read ↗ |
| Feb 5, 2025 | Annual report 20-F | Read ↗ |
| Jan 31, 2024 | Annual report 20-F | Read ↗ |
| Feb 1, 2023 | Annual report 20-F | Read ↗ |
| Sep 15, 2022 | Tender offer SC TO-T | Read ↗ |
| Feb 2, 2022 | Annual report 20-F | Read ↗ |
| Nov 24, 2021 | Tender offer SC TO-T | Read ↗ |
| Feb 3, 2021 | Annual report 20-F | Read ↗ |
| Feb 5, 2020 | Annual report 20-F | Read ↗ |
| Feb 4, 2019 | Annual report 20-F | Read ↗ |
| Feb 8, 2018 | Annual report 20-F | Read ↗ |
| Feb 9, 2017 | Annual report 20-F | Read ↗ |
Source: Novo Nordisk A/S's EDGAR filing history, the last ten years. The labels are the form types and 8-K item numbers the company filed under, not a reading of what it wrote — an item 5.02 can be a chief executive fired or a director retiring on schedule — so each row links to the filing.
More on NVO
Company overviewEverything on NVO in one place, with the price.Who owns itEvery manager reporting a position in NVO.Funds holding itWhich funds and ETFs hold NVO, and how big a bet.LobbyingWhat NVO spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NVO's account, and who they worked for.PatentsWhat NVO is filing at the patent office.